Equities

Laboratoires Euromedis SA

Laboratoires Euromedis SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 22 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments192732
Total Receivables, Net9.591119
Total Inventory9.601312
Prepaid expenses1.271.351.63
Other current assets, total00.000.01
Total current assets395264
Property, plant & equipment, net0.634.324.40
Goodwill, net--2.542.63
Intangibles, net0.030.090.14
Long term investments6.301.051.15
Note receivable - long term------
Other long term assets0.00--0.00
Total assets466073
LIABILITIES
Accounts payable7.817.3111
Accrued expenses1.101.901.96
Notes payable/short-term debt000
Current portion long-term debt/capital leases9.83----
Other current liabilities, total1.660.670.66
Total current liabilities209.8813
Total long term debt01315
Total debt9.831315
Deferred income tax----0.35
Minority interest--0.180.24
Other liabilities, total3.282.332.54
Total liabilities242532
SHAREHOLDERS EQUITY
Common stock5.756.026.02
Additional paid-in capital9.739.219.21
Retained earnings (accumulated deficit)4.481926
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total2.63----
Total equity233541
Total liabilities & shareholders' equity466073
Total common shares outstanding2.852.992.99
Treasury shares - common primary issue0.030.020.02
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.